ISSN: 2155-952X

バイオテクノロジーとバイオマテリアル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • シェルパ・ロミオ
  • Jゲートを開く
  • Genamics JournalSeek
  • アカデミックキー
  • 研究聖書
  • 中国国家知識基盤 (CNKI)
  • Global Online Research in Agriculture (AGORA) へのアクセス
  • 電子ジャーナルライブラリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • SWBオンラインカタログ
  • 仮想生物学図書館 (vifabio)
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

Ropivacaine versus Bupivacaine in Postoperative Pain Control

Noha Ahmed Mansour, Fouad A-Mahdy AL-Belasy, Mohamed Abdel-Monem Tawfik and Hamdy A Marzook

Objective: The aim of this study was to compare between 2 types of long acting anesthetics: bupivacaine 0.5% and ropivacaine 0.75%, in terms of their duration of anesthesia, duration of analgesia and their effect in controlling postoperative pain after surgical removal of impacted lower third molars. Material and Methods: This study was conducted on fifty subjects referred to the Oral Surgery Department, Faculty of Dentistry, Mansoura University, for surgical removal of impacted lower third molar. Subjects were randomly assigned prior to surgery into 2 nerve block injections; the first group (group A) for an inferior alveolar nerve block (IANB) using bupivacaine and the second group (group B) for an IANB using ropivacaine. In each group, the patient’s age, sex, type of impaction, severity of impaction was recorded. Time from the start of surgery till removal of impacted molar was taken as duration of surgery. Patients were instructed not to take any analgesics until numbness of lip and tongue receded.The time from onset of anaesthesia to when numbness of the lip and tongue receded as assessed by pricking is taken as the duration of anaesthesia. The time from the start of numbness to when the subject first requested a dose of oral analgesic (NSAID) was taken as duration of analgesia. Pain was assessed preoperatively and postoperatively, then patients instructed to record the extent of their pain at 3, 6, 9, and 12 hours on the day of surgery (D1), on the second (D2) and third days (D3) postoperatively. Post-operative analgesic consumption, inability to sleep because of pain, degree of overall satisfaction with the anaesthetic efficacy and postoperative pain management were considered. Results: The median duration of anaesthesia for the 7.5 mg/ml concentration of ropivacaine was approximately 6 hours, and for bupivacaine 5 mg/ml was approximately 7 hours. Bupivacaine can provide analgesia for 10.3 hours while ropivacaine can provide analgesia during the first 9.6 hours which is the period of maximum pain after third molar surgery. Conclusion: As regards a comparison of the study drugs with respect to post-operative pain experience, analgesic need and consumption, bupivacaine and ropivacaine appear to have equivalent efficacy.